Tabernaecorymbosine ACAS# 1262306-81-9 |
Quality Control & MSDS
Package In Stock
Number of papers citing our products
| Cas No. | 1262306-81-9 | SDF | Download SDF |
| PubChem ID | N/A | Appearance | Powder |
| Formula | C44H54N4O6 | M.Wt | 734.9 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Tabernaecorymbosine A Dilution Calculator
Tabernaecorymbosine A Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.3607 mL | 6.8036 mL | 13.6073 mL | 27.2146 mL | 34.0182 mL |
| 5 mM | 0.2721 mL | 1.3607 mL | 2.7215 mL | 5.4429 mL | 6.8036 mL |
| 10 mM | 0.1361 mL | 0.6804 mL | 1.3607 mL | 2.7215 mL | 3.4018 mL |
| 50 mM | 0.0272 mL | 0.1361 mL | 0.2721 mL | 0.5443 mL | 0.6804 mL |
| 100 mM | 0.0136 mL | 0.068 mL | 0.1361 mL | 0.2721 mL | 0.3402 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Alpinigenine
Catalog No.:BCN0463
CAS No.:14028-91-2
- 2,4-Dihydroxy-6-methoxy-3,5-diprenylacetophenone
Catalog No.:BCN0462
CAS No.:123999-38-2
- 4,5-Dioxodehydroasimilobine
Catalog No.:BCN0461
CAS No.:82644-81-3
- 3,8-Di-O-methylellagic acid 2-O-(5'-O-acetyl)arabinofuranoside
Catalog No.:BCN0460
CAS No.:365540-09-6
- 5-exo-Hydroxyborneol
Catalog No.:BCN0459
CAS No.:32751-73-8
- (+/-)-N-methylcoclaurine
Catalog No.:BCN0458
CAS No.:1472-62-4
- Bis(2-ethylhexyl) terephthalate
Catalog No.:BCN0457
CAS No.:6422-86-2
- Toxyloxanthone B
Catalog No.:BCN0456
CAS No.:50875-24-6
- V1 iridoid
Catalog No.:BCN0455
CAS No.:87441-71-2
- Acronyculatin Q
Catalog No.:BCN0454
CAS No.:2287183-54-2
- Mecambridine
Catalog No.:BCN0453
CAS No.:31098-60-9
- Acropyrone
Catalog No.:BCN0452
CAS No.:1381875-14-4
- Flindulatin
Catalog No.:BCN0465
CAS No.:521-44-8
- (±)-Cleroindicin F
Catalog No.:BCN0466
CAS No.:94535-01-0
- p-O-Farnesylcoumaric acid
Catalog No.:BCN0467
CAS No.:939769-47-8
- 6,4'-Dihydroxy-5,7-dimethoxyflavanone
Catalog No.:BCN0468
CAS No.:6951-57-1
- 5-endo-Hydroxyborneol
Catalog No.:BCN0469
CAS No.:68738-10-3
- 1-O-p-Coumaroylglucose
Catalog No.:BCN0470
CAS No.:7139-64-2
- 1-O-Cinnamoylglucose
Catalog No.:BCN0471
CAS No.:40004-96-4
- 1,4-Dihydro-1-methyl-4-oxonicotinamide
Catalog No.:BCN0472
CAS No.:769-49-3
- Acrotrione
Catalog No.:BCN0473
CAS No.:2349327-31-5
- Polypodine B 20,22-acetonide
Catalog No.:BCN0474
CAS No.:159858-85-2
- 2',3'-Dehydromarmesin
Catalog No.:BCN0475
CAS No.:28664-60-0
- (±)-8-Gingerol
Catalog No.:BCN0476
CAS No.:77398-92-6
Taburnaemines A-I, Cytotoxic Vobasinyl-Iboga-Type Bisindole Alkaloids from Tabernaemontana corymbosa.[Pubmed:29319316]
J Nat Prod. 2018 Mar 23;81(3):562-571.
Nineteen vobasinyl-ibogan-type bisindole alkaloids, including nine new compounds, taburnaemines A-I (1-9), were isolated from the twigs and leaves of Tabernaemontana corymbosa. The structures and absolute configurations of the new alkaloids were determined by a combination of MS, NMR, and ECD analyses. Alkaloids 1-5 contain a rare 1,3-oxazinane moiety in the vobasinyl unit, while 6 has an uncommon 1,3-oxazolidine moiety in the iboga unit. The absolute configurations of alkaloid 1 and the known alkaloid Tabernaecorymbosine A (10) were confirmed by single-crystal X-ray diffraction analysis. All of the bisindole alkaloids, except 2 and 16'-decarbomethoxyTabernaecorymbosine A (14), showed antiproliferative activity (IC50 2.6-9.8 muM) against several human cancer cell lines, including A-549, MDA-MB-231, MCF-7, KB, and P-glycoprotein-overexpressing multidrug-resistant KB cells. The preliminary structure-activity relationship correlations are also discussed.
New vobasinyl-ibogan type bisindole alkaloids from Tabernaemontana corymbosa.[Pubmed:25449423]
Fitoterapia. 2015 Jan;100:150-5.
Ten vobasinyl-ibogan type bisindole alkaloids, including three new ones, tabercorines A-C (1-3), and a new natural product, 17-acetyl-Tabernaecorymbosine A (4), were isolated from the twigs and leaves of Tabernaemontana corymbosa. Their structures were elucidated on the basis of spectroscopic data, and the NMR data of 17-acetyl-Tabernaecorymbosine A (4) was assigned and reported for the first time. The absolute configurations of 1-4 were determined by CD exciton chirality method. All new compounds were evaluated for in vitro cytotoxicity against various human cancer cell lines. Compounds 1 and 4 showed significant inhibitory effects with IC50 values comparable to those of cisplatin.
